Themis Medicare
85.80
-1.04(-1.20%)
Market Cap₹789.70 Cr
PE Ratio-46.06
IndustryHealthcare
Company Performance:
1D-1.20%
1M+7.67%
6M-14.44%
1Y-48.20%
5Y+178.21%
View Company Insightsright
More news about Themis Medicare
04Aug 25
Themis Medicare Reports Q1 Net Loss of 142 Million Rupees Amid Revenue Decline
Themis Medicare, a pharmaceutical company, reported a consolidated net loss of ₹142.00 million in Q1, contrasting with a ₹247.00 million profit in the same quarter last year. Revenue decreased by 24.92% to ₹976.00 million from ₹1,300.00 million. EBITDA turned negative at ₹101.00 million loss, compared to a positive ₹292.00 million in the previous year's quarter.
 no imag found
20May 25
Themis Medicare Reports Q4 Revenue Decline and Net Loss
Themis Medicare's Q4 financial results show a significant downturn. The company reported a net loss of ₹96.60 million, contrasting with a profit of ₹66.40 million in the same quarter last year. Revenue decreased by 26.70% compared to the previous quarter. This marks a notable shift from the ₹5.20 million profit in the preceding quarter, indicating volatility in the company's financial performance.
 no imag found
Themis Medicare
85.80
-1.04
(-1.20%)
1 Year Returns:-48.20%
Industry Peers
Sun Pharmaceutical
1,737.00
(-2.73%)
Divis Laboratories
6,408.50
(-1.01%)
Torrent Pharmaceuticals
4,333.30
(-1.51%)
Cipla
1,348.20
(-0.73%)
Dr Reddys Laboratories
1,286.30
(-2.50%)
Lupin
2,301.90
(-0.92%)
Mankind Pharma
2,247.60
(-1.41%)
Zydus Life Science
921.70
(-1.79%)
Aurobindo Pharma
1,220.40
(-0.02%)
Alkem Laboratories
5,639.50
(-1.96%)